Glaukos
Buying intent
31 tracked signals | Top 15 topics are below | Marketing and Sales are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Glaukos's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
3d ago
3d ago
4d ago
4d ago
30d ago
4d ago
9d ago
3d ago
3d ago
3d ago
3d ago
18d ago
5d ago
30d ago
3d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Glaukos
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
13 people across every department at Glaukos, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileAt Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.
Top accounts researching Glaukos
names withheld on the public pageThese are companies whose own people brought up Glaukos unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
6,524 companies · 23,607 people are researching Health Care
Glaukos's own team shows 3 signals on this topic. No one outside Glaukos has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Patient Care3,825 cos · 15,451 people
- Hiring66,174 cos · 318,882 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Marketing — 2 people; Leadership — 1 person; Sales — 1 person
What's been said
public posts mentioning GlaukosUp to 9 public excerpts naming Glaukos from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
Congratulations to Dr. Thomas Mauger and the team at WVU EYE INSTITUTE for their partnership and recent acquisition of the O2n™ system to perform FDA-approved Epioxa™ (riboflavin 5’-phosphate ophthalmic solution) cross-linking treatment. Thank you for the collaboration—we appreciate all that you do! #DoctorRecognition #PhysicianAppreciation #HealthcareCommunity #Teamwork #Epioxa #O2NSystem #HealthcareInnovation #Glaukos #LivingwithKC #InterventionalKC #InterventionalKeratoconus #IKC
May 2026Congratulations to Dr. Joseph Christenbury and his entire team at Eye Consultants of Atlanta for performing the first FDA-approved Epioxa™ (riboflavin 5'-phosphate ophthalmic solution) procedure in Georgia covered by a commercial insurance plan. Their leadership in embracing new therapeutic options continues to elevate care for patients with keratoconus. Epioxa ™ is the first and only epithelium-on oxygen-enriched corneal collagen cross-linking treatment for keratoconus. The most common adverse reaction is conjunctival hyperaemia or redness of the eye. For additional Important Safety Information, please visit https://lnkd.in/gqr4ZjWi . #HealthcareCommunity #Teamwork #HealthcareInnovation #Glaukos #AdvancingCare #ImprovingPatientCare
May 2026Congratulations to Dr. Patrick Laber and the team at Raleigh Ophthalmology for their partnership and recent acquisition of the O2n™ system to perform FDA-approved Epioxa™ (riboflavin 5’-phosphate ophthalmic solution) cross-linking treatment. Thank you for the collaboration—we appreciate all that you do! #DoctorRecognition #PhysicianAppreciation #HealthcareCommunity #Teamwork #Epioxa #O2NSystem #HealthcareInnovation #Glaukos #LivingwithKC #InterventionalKC #InterventionalKeratoconus #IKC
May 2026We’re hiring at Glaukos Corporation! Seeking an experienced Quality Control Laboratory Manager to join our QC team supporting innovative ophthalmic therapies and combination products. Great opportunity for a strong chemistry leader who enjoys team development, cross-functional collaboration, continuous improvement, and working in a dynamic GMP environment. Apply here: https://lnkd.in/gMPcbCz8
May 2026Congratulations to Dr. Vance Thompson and the entire team at Vance Thompson Vision who performed the first FDA-approved Epioxa™ (riboflavin 5'-phosphate ophthalmic solution) procedure yesterday in South Dakota! Their leadership in embracing new therapeutic options continues to elevate care for patients with keratoconus. Epioxa ™ is the first and only epithelium-on oxygen-enriched corneal collagen cross-linking treatment for keratoconus. The most common adverse reaction is conjunctival hyperaemia or redness of the eye. For additional Important Safety Information, please visit https://lnkd.in/gqr4ZjWi . #HealthcareCommunity #Teamwork #HealthcareInnovation #Glaukos #AdvancingCare #ImprovingPatientCare
May 2026We’re proud to share that Neel Vaidya, MD, MPH, MBA and the team at Chicago Cornea Consultants have completed their first Epioxa™ (riboflavin 5’-phosphate ophthalmic solution) crosslinking procedure. An exciting step forward in advancing the treatment for keratoconus. Epioxa™ is the first and only epithelium-on oxygen-enriched corneal collagen cross-linking treatment for keratoconus. We remain committed to advancing care with teamwork, innovation, and a focus on patients. Visit https://lnkd.in/gY4ywD3T for Important Safety Information. #HealthcareCommunity #Teamwork# #Epioxa #HealthcareInnovation #Glaukos #LivingwithKC #InterventionalKC #InterventionalKeratoconus
Apr 2026Strategic priorities
Earnings call; SEC filingsGo to Market; Cash Flow; Market Access
What changed recently
Earnings call; SEC filingsGo to Market; Cash Flow; Market Access